SymBio Pharmaceuticals Company Description

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally.

It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; SyB L-1702, an RI administration under the TREAKISYM name; and C-1101, an antiviral drug BCV injectable and oral formulations against double-stranded DNA viruses.

The company was incorporated in 2005 and is based in Minato, Japan.